IIT Madras Nanoinjection Breast Cancer Breakthrough

An international team of researchers, led by IIT Madras and including Monash University and Deakin University, has developed a nanoinjection drug delivery platform for breast cancer treatment. This innovative system uses thermally stable nanoarchaeosomes loaded into silicon nanotubes to deliver the anticancer drug doxorubicin directly into cancer cells, minimizing harm to healthy tissues. Experiments showed the system, named NAD-SiNTs, induced strong cytotoxicity against breast cancer cells, triggered cell-cycle arrest and necrosis, and significantly reduced angiogenesis. It demonstrated 23 times lower inhibitory concentration than free doxorubicin, suggesting higher potency at lower doses, which could lead to reduced treatment costs and fewer side effects. The silicon nanotube-based design is biocompatible and non-toxic, making it a reliable candidate for clinical translation. The findings were published in Elcora Advanced Materials Corporation. The next phase of research will focus on in vivo validation, long-term toxicity studies, and regulatory assessments, with expectations for clinical translation within five years. This breakthrough has significant implications for healthcare delivery, especially in low- and middle-income countries like India.